Log in
NASDAQ:QURE

Uniqure Stock Forecast, Price & News

$36.83
+0.85 (+2.36 %)
(As of 09/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$36.00
Now: $36.83
$37.60
50-Day Range
$35.98
MA: $39.43
$42.25
52-Week Range
$35.76
Now: $36.83
$76.69
Volume258,760 shs
Average Volume487,750 shs
Market Capitalization$1.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.17
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More
Uniqure logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.67 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QURE
CUSIPN/A
Phone31-20-240-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.28 million
Book Value$7.41 per share

Profitability

Net Income$-124,200,000.00
Net Margins-2,553.30%

Miscellaneous

Employees212
Market Cap$1.64 billion
Next Earnings Date10/26/2020 (Estimated)
OptionableOptionable
$36.83
+0.85 (+2.36 %)
(As of 09/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Uniqure (NASDAQ:QURE) Frequently Asked Questions

How has Uniqure's stock price been impacted by COVID-19 (Coronavirus)?

Uniqure's stock was trading at $47.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QURE shares have decreased by 22.5% and is now trading at $36.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Uniqure?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 2 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Uniqure
.

When is Uniqure's next earnings date?

Uniqure is scheduled to release its next quarterly earnings announcement on Monday, October 26th 2020.
View our earnings forecast for Uniqure
.

How were Uniqure's earnings last quarter?

Uniqure NV (NASDAQ:QURE) issued its quarterly earnings data on Thursday, July, 30th. The biotechnology company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.31. The biotechnology company had revenue of $1.54 million for the quarter, compared to analysts' expectations of $17.87 million. Uniqure had a negative net margin of 2,553.30% and a negative return on equity of 43.95%.
View Uniqure's earnings history
.

What price target have analysts set for QURE?

13 brokers have issued twelve-month price targets for Uniqure's shares. Their forecasts range from $56.00 to $98.00. On average, they anticipate Uniqure's share price to reach $75.92 in the next year. This suggests a possible upside of 106.1% from the stock's current price.
View analysts' price targets for Uniqure
.

Who are some of Uniqure's key competitors?

What other stocks do shareholders of Uniqure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Uniqure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), Square (SQ) and Verastem (VSTM).

Who are Uniqure's key executives?

Uniqure's management team includes the following people:
  • Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 47)
  • Dr. Sander van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & GM of Amsterdam (Age 65)
  • Mr. Jonathan Garen, Chief Bus. Officer (Age 53)
  • Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Dr. Scott T. McMillan, Chief Operations Officer (Age 60)

What is Uniqure's stock symbol?

Uniqure trades on the NASDAQ under the ticker symbol "QURE."

How do I buy shares of Uniqure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Uniqure's stock price today?

One share of QURE stock can currently be purchased for approximately $36.83.

How big of a company is Uniqure?

Uniqure has a market capitalization of $1.64 billion and generates $7.28 million in revenue each year. The biotechnology company earns $-124,200,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis. Uniqure employs 212 workers across the globe.

What is Uniqure's official website?

The official website for Uniqure is www.uniqure.com.

How can I contact Uniqure?

Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]

This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.